Varian cancer treatment system cleared in US:
This article was originally published in Clinica
VariSource, Varian Associates' high dose rate remote afterloader cancer treatment system, has been given 510(k) clearance for marketing in the US. Frequently used in the treatment of gynaecological and lung cancers, the system employs a catheter and applicators to position a radioactive isotope directly in or next to tumour sites. It is used to administer most treatments on an outpatient basis and can be used to supplement conventional external beam radiotherapy and certain surgical procedures. VariSource is produced at Varian's factory in Crawley in the UK.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.